Pharmaceutical Executive-07-01-2018

The role of insurance and risk management in protecting middle-market distributors from the growing opioid multi-district litigation (MDL).

Outlining a real-world example in which building and operationalizing a patient- and customer-centric commercialization strategy drove a successful launch from a “standing start.”

Pharm Exec convenes an expert panel at CBI’s Pharmaceutical Compliance Congress to discuss new ways to navigate the many complexities when it comes to the crucial task of assessing business and risk in the life sciences.

While the field of regenerative medicine has grown considerably since the ’90s-in innovation and acceptance-entrenched companies such as Athersys are looking to forge new advances in the stem cell arena by transforming promising science into real-world treatments.

With blockchain still in the potential but not proven area of the pharma enterprise, when is the technology the right choice for you?

How navigating compliance risks requires so much more than policies and procedures.

Streamlined clinical research, more guidance speed new cures to patients.

Exploring the prospects-and related challenges-for Chinese life science as it aggressively pursues new growth areas.

The Indian pharmaceutical industry is traditionally known as a global powerhouse for the production of bulk drugs and generics, but less heralded is the growth India has made on the pharma world stage in several other areas, including biotechnology and R&D.

Click the title above to open the Pharmaceutical Executive July 2018 issue in an interactive PDF format.